Q2 Implantica

Interim Report January – June 2025

FINANCIAL SUMMARY

Figures within parentheses refer to the preceding year.

Second quarter

- Net sales decreased 22% to TEUR 433 (554) due to the launch of the randomized clinical trial with surgeons accumulating patients for the trial.
- Adjusted gross margin amounted to 90% (91%).
- Operating loss (EBIT) decreased to TEUR 4,525 (5,869).
- Loss after tax decreased to TEUR 5,448 (6,431).
- Basic and diluted loss per Class A share amounted to EUR 0.08 (0.09).
- Cash and short-term investments as at the end of the period of MEUR 56.3.

First six months

- Net sales increased 2% to TEUR 1,178 (1,150).
- Adjusted gross margin amounted to 94% (91%).
- Operating loss (EBIT) decreased to TEUR 8,698 (12,956).
- Loss after tax decreased to TEUR 8,212 (9,903).
- Basic and diluted loss per Class A share amounted to EUR 0.12 (0.14).

Significant Events

IN THE SECOND QUARTER OF 2025

- FDA PMA Submission Completed – Submitted third and final module of the U.S. FDA pre-market approval (PMA) application for RefluxStop®, including responses to questions on the second module; Feedback on module 3 expected in the near-term
- Produced and completed initial testing on new multi-cavity production tool for RefluxStop® to support launch of manufacturing in U.S. and manage ramp-up of U.S. production (pending FDA approval)
- Additional preparations for U.S. market launch (pending FDA approval) included U.S. payer and reimbursement activities, finalizing new production facility of RefluxStop® in U.S. and launching our RCT (randomized clinical trial), as a heavyweight cornerstone in building global leadership in acid reflux care
- Positive NICE Guidance in the UK – UK's National Institute for Health and Care Excellence (NICE) issued positive guidance for the use of RefluxStop® in NHS hospitals for patients with ineffective esophageal motility (IOM/IEM), potentially transforming treatment access for millions and influencing global policy

AFTER THE END OF THE PERIOD

- Landmark 5-Year Clinical Study Results – Two peer-reviewed articles were published in *Surgical Endoscopy* on our pivotal study results; one publication confirmed outstanding long-term safety and effectiveness outcomes, and the second publication highlighted RefluxStop®'s excellent outcomes in food passageway-related sequelae, which is common in standard of care
- Randomized Clinical Trial (RCT) Launch – First RCT comparing RefluxStop® with Nissen fundoplication; patient recruitment underway accumulating patients across participating hospitals. While this trial preparation led to a 20% year-on-year revenue decline for Q2, the impact is expected to ease once study recruitment stabilizes
- Spanish Market Expansion – Three new hospitals added, totaling 19 centers offering RefluxStop® in Spain, with a healthcare sytem receptive for new and better patient care, which is a fantastic launch since 2023
- First UK National Users Meeting – Convened 21 top anti-reflux experts to discuss real-world results, operating technique and the opportunities arising from NICE's positive recommendation

Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum – **Building Global Leadership in Acid Reflux Care is exciting!**

In Q2, we supercharged our top strategic priorities ahead of U.S. launch, pending FDA approval. This involved: U.S. market launch preparations, RefluxStop®'s U.S. production ramp planning, U.S. payer and reimbursement strategies, launch of the boldest clinical initiatives (e.g. randomized clinical trial), securing pivotal endorsements from top government agencies (e.g. NICE in UK) and further strengthening our global presence, setting the stage for the next chapter in RefluxStop®'s journey to redefine acid reflux treatment.


Dr. Peter Forsell, CEO Implantica

This past quarter has been one of remarkable progress, excellent scientific validation, and strategic positioning for Implantica, as we continue to advance RefluxStop® toward becoming the new global standard in acid reflux surgery.

Final Steps Toward U.S. Market Entry: FDA Premarket Approval (PMA)

One of our most important achievements was the submission of the third and final module of our U.S. FDA pre-market approval (PMA) application for RefluxStop®. This final submission, together with our formal responses to Module 2, marks a significant milestone in our regulatory journey toward entering the U.S. market — one of the largest and most influential in the world. Answers regarding Module 2, the clinical module, addressed what we believe were minor findings, while Module 3 contained rigorous product validation, including bench testing and biocompatibility data. In both submissions, we were able to present robust, conclusive data that we believe not only meets the FDA's stringent standards but may well exceed them. The PMA process is now largely in the FDA's hands, and we anticipate feedback on Module 3 in the near term. We are confident that our strong clinical and technical data positions us favorably for the next stages in this approval process.

Launching a Landmark Clinical Trial (RefluxStop® vs. standard of care Nissen fundoplication)

Another major milestone was the launch of the first-ever randomized clinical trial (RCT) comparing RefluxStop® to a current surgical gold standard, Nissen fundoplication. This landmark trial involves substantial site training, database development work and administrative actions related to the patient recruitment process that has been performed in participating hospitals. The trial is designed to provide pivotal evidence that will solidify and shape future clinical guidelines, accelerate reimbursement decisions, and broaden payer coverage both in Europe and the U.S. During Q2, many key Hospitals spent significant time and resources to prepare for this game-changing RCT and to build-up the necessary patient pipeline for this study, which, as expected, has temporarily impacted revenues in Q2 — resulting in about a 20% decline compared to Q2 2024, since surgeons have lined up and saved patients for the RCT. We view this as a strategic investment. Once recruitment reaches its steady pace, we expect the revenue impact of this important study involving >10 of our key users of RefluxStop® to lessen. The long-term benefits of the trial will be significant and far-reaching.

NICE Endorsement Opens New Horizons

In the UK, we achieved an important breakthrough in market access. The National Institute for Health and Care Excellence (NICE) issued positive Interventional Procedures Guidance (IPG) recommendations for RefluxStop®, enabling GORD/GERD patients with Ineffective Oesophageal Motility (IOM/IEM) to be treated in NHS public hospitals. This is a critical patient group — up to 40–50% of acid reflux sufferers have IOM/IEM, a condition for which traditional surgical approaches are often unsuitable or ineffective. NICE's decision not only opens access in the UK but, given its global influence on healthcare policy, could transform the treatment landscape for millions of patients worldwide. The UK healthcare system's willingness to rapidly integrate innovative and effective treatments like RefluxStop® is a testament to its patient-focused approach.

Defining a new Gold Standard: 5-Year Clinical Results

Our clinical evidence reached new heights with the publication of two landmark peer-reviewed articles in *Surgical Endoscopy*, jointly produced by the Society of American Gastrointestinal and Endoscopic Surgeons

(SAGES) and the European Association for Endoscopic Surgery (EAES). These publications present the 5-year results on RefluxStop® from our multicenter pivotal trial and confirm not only exceptional long-term safety and effectiveness but also remarkable outcomes in terms of food passageway-related sequelae in relation to standard of care. Key findings include:

- **Unmatched Safety**: No device-related adverse events over the entire 5-year period
- **Freedom from Medication**: 97.9% off daily PPI medication at 5 years (compared to 100% on PPIs pre-surgery)
- **Freedom from Severe Side-effects:**
  - 97.9% of patients free from adverse event dysphagia and odynophagia
  - 95.7% with gas-bloating eliminated, improved, or unchanged
  - 100% retaining the ability to belch or vomit
- **Patient's Quality of Life**: GERD-HRQL questionnaire scores improved by a median of 90%
- **Most Decisive pH Test**: Acid exposure time (24-hour pH monitoring), the only objective acid reflux measure, reduced by 90.4% ($p<0.001$)

These outstanding results are not just numbers — they indicate a paradigm shift in the treatment of acid reflux, showing that it is possible to deliver durable, life-changing outcomes without the significant side effects that have traditionally accompanied surgical interventions.

Here you find the full 5-year published research articles (link):

- Food Passageway Outcomes
- Effectiveness & Safety Outcomes

Expanding Global Commercial Footprint

On the commercial front, we continue to build strong momentum in our current key markets in Europe while also focusing on the U.S. market, poised to experience transformative growth with tremendous market development preparations, ahead of the pending U.S. market approval.

Spain remains one of our fastest-growing regions, with three new centers of excellence added since Q1, bringing the total to 19 hospitals offering RefluxStop®. In the UK, we hosted our first National Users Meeting, bringing together 21 leading anti-reflux experts to exchange real-world experiences and explore the opportunities created by NICE's positive guidance.

For the past 2 years we have been addressing U.S.-based production capabilities to ensure we are fully prepared to meet the expected surge in demand upon market entry. This includes the completion and initial validation of a new RefluxStop® U.S. production tool, which took 1.5 years to develop, to manufacture the device domestically (pending FDA approval) to save shipping costs and eventual custom fees. We are also finalizing a new production facility for RefluxStop® in the U.S. These strategic preparations are key to supporting rapid adoption and scaling in one of the world's largest healthcare markets.

In short, the enthusiasm and expertise of our growing surgical community will be a powerful driver of adoption in the years ahead.

Showcasing Innovation on the Global Stage

Our global presence was strongly felt at Digestive Disease Week (DDW) 2025 in San Diego — one of the world's most influential gastroenterology and surgery conferences. RefluxStop® was featured in multiple presentations, including positive outcomes in patients converted from failed standard-of-care surgeries, excellent one-year results from a Swiss institution's first 100 patients, and a favorable review of RefluxStop® during the "Technologies and Procedural Innovation" session by Dr. Reginald Bell, former President of the American Foregut Society. This level of exposure in the U.S. surgical community further strengthens our position ahead of FDA approval.

Our eHealth Platform

Implantica has a large number of fantastic patented implant solutions that have the potential to revolutionize healthcare. Two-thirds of this pipeline is based on our two platform technologies. Our eHealth platform is built to be able to monitor patient treatment and change the treatment on distance, a unique and patent-protected solution covered by 25,000 pages of patents. Advanced solutions inside the body require more power, and, therefore, we have developed a superior wireless energizing platform, which opens up enormous possibilities. Currently these projects are on a low burner prioritizing the U.S. launch (pending FDA approval), however, these far-reaching projects have the potential for Implantica to become a multiproduct-leading healthcare player, once RefluxStop® has been successfully launched (pending FDA approval) in the U.S.

Looking Ahead

In summary, this has been a quarter of decisive steps forward. From regulatory progress and groundbreaking clinical validation to market access breakthroughs and commercial expansion, we are steadily building the foundation for RefluxStop® to redefine acid reflux surgery worldwide. With the continued dedication of our team, the trust of our surgical partners, the growing weight of our clinical evidence, and the imminent U.S.-launch, pending FDA approval, we conclude that the RefluxStop® journey has all the attributes to be very fruitful and exciting for all stakeholders, also in the near term, and brings us ever closer to our mission of transforming the lives of millions of patients.

Yours sincerely,
Dr. med. Peter Forsell, *Surgeon and Inventor*
CEO and Founder, Implantica

IMPLANTICA IN BRIEF

Implantica is a MedTech group committed to providing effective care for serious health conditions and improving patient quality of life by bringing advanced technology into the body. Simultaneously, Implantica aims to reduce overall costs and improve efficiency in the healthcare system. The therapies Implantica develops are based on implants, which are inserted into the patient's body to replace bodily functions and/or treat diseases.

Implantica's most progressed product, RefluxStop®, represents a strong potential for a paradigm shift in the treatment of GERD, based on excellent clinical evidence. Acid reflux has a significant impact on patient quality of life and can induce serious complications, including increased risk for esophageal cancer.

GERD patients rely today, to a large extent, on PPIs – a drug therapy which calms the symptoms of GERD. Ultimately, with PPI treatment, the side effects are severe, involving a risk of early death (as published by Yan Xie et al. on >150,000 U.S. veterans taking PPI for 10 years[1]). Reflux of stomach fluid is not prevented by PPIs and the risk for developing esophageal cancer remains. According to a study by Brusselaers et al. from Karolinska Institute[2], 38% of all patients dying from esophageal cancer were PPI users.

Alternative surgical procedures available today are plagued with complications, including affecting the food passageway and causing swallowing difficulties.

In addition to RefluxStop®, Implantica has developed two platform technologies: an eHealth platform and a wireless energizing platform as well as a broad, patent-protected product pipeline, two-thirds of which are based on the company's two platform technologies.

Bringing advanced technology and smart medical implants into the body requires enough power to activate a device inside the body long-term, which is the reason why a wireless energising platform has been developed. The eHealth platform is necessary for communicating with and reprogramming implants and adjusting treatment on distance.

These platform technologies are covered by a multitude of patents and patent applications.

References:

(1) Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019;365:11580.

(2) Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018;53:172-7.

Top ten shareholders as of 30 June 2025

Name	Capital (%)
Peter Forsell	46.6%
Handelsbanken Fonder	8.8%
EFG Bank	6.9%
UBS	3.7%
Avanza Pension	2.8%
UBP	2.8%
SEB Life	2.7%
SIX SIS AG	1.6%
Nordea Liv	1.4%
Stephan Siegenthaler	1.3%

Financial performance in brief

Figures in parentheses within the following section refer to the corresponding period in the preceding year.

Net sales

During the second quarter, net sales amounted to EUR 433 thousand (554), corresponding to a decrease of EUR 121 thousand or -22%. The year-on-year decrease reflects the launch of the randomized clinical trial with surgeons accumulating patients for the trial planned to commence in the second half of 2025. Implantica is currently exclusively marketing its lead product, RefluxStop®, to selected Key Opinion Leaders in Europe.

For the first six months, sales amounted to EUR 1,178 thousand (1,150), corresponding to an increase of EUR 28 thousand or 2%.

Cost of sales and gross margin

Cost of sales during the second quarter amounted to EUR 351 thousand (357). The Cost of sales considers two types of expenses. First, indirect costs of straight-line amortization of capitalized development costs relating to RefluxStop®. Second, Other cost of sales, which relates to direct costs for purchasing goods and services from the Group's outsourcing partners.

In the second quarter, adjusted gross margin, i.e., gross margin excluding amortization, amounted to 90% (91%).

The cost of sales over the first six months of the year amounted to EUR 681 thousand (713). The adjusted gross margin[1], amounted to 94% (91%).

Operating expenses and EBIT

In the second quarter operating loss (EBIT) amounted to EUR 4,525 thousand (5,869), a decrease of EUR 1,344 thousand or 23%. Research and development costs made up EUR 1,385 thousand (3,012), corresponding to a decrease of EUR 1,627 thousand or 54%. The decrease in Research and development costs were primarily driven by lower expenses relating to the FDA submission and patents.

General and administrative costs amounted to EUR 3,222 thousand (3,054), an increase of EUR 168 thousand or 6% driven by increased costs for share-based compensation and investments relating to quality management.

For the first six months of the year, the operating loss (EBIT) amounted to EUR 8,698 thousand (12,956). Where Research and development cost made up EUR 2,961 thousand (7,339), corresponding to a decrease of EUR 4,378 thousand or 60% compared to the first six months of 2024. General and administrative costs increased to EUR 6,234 thousand (6,054), an increase of EUR 180 thousand or 3%.

Financial income and expenses

Financial income amounted to EUR 744 thousand (301) during the second quarter. Financial expenses amounted to EUR 1,664 thousand (863) over the quarter driven by foreign exchange losses.

For the first six months of the year, Financial income amounted to EUR 610 thousand (3,938) and Financial expenses totaled EUR 117 thousand (883).

Income taxes

The Group reported a tax expense of EUR 3 thousand (0) in the second quarter. The tax expense for the quarter is mainly explained by changes in deferred tax assets. For the first six months of the year, the Group reported a tax expense of EUR 7 thousand (2).

Net earnings

The Group reported a net loss of EUR 5,448 thousand (6,431) for the second quarter, a decrease of EUR 983 thousand driven by lower operating expenses.

For the first six months of the year, the net loss amounted to EUR 8,212 thousand (9,903), a decrease of EUR 1,691 thousand.

[1] Adjusted gross profit as a percentage of Net sales. Where Adjusted gross profit is defined as Net sales minus cost of sales, plus amortization of development costs.

Equity and liabilities

As of 30 June 2025, the Group's equity amounted to EUR 92.8 million (111.7) with an equity ratio of 98%, compared to 96% at 30 June 2024.

As of 30 June 2025, the Group did not have any interest-bearing debt.

Cash flow and liquidity

During the second quarter net cash outflow from operating activities amounted to EUR 3,919 thousand (6,537).

Net cash outflow from operating activities over the first six months of 2025 amounted to EUR 8,444 thousand (13,002).

As of 30 June 2025, Implantica held cash and short term investments of EUR 56.3 million.

Auditor's review

This report has not been reviewed by the company's auditors.

Consolidated interim financial statements

Condensed consolidated statement of profit or loss

	Apr to Jun		Jan to Jun		Jan to Dec
in thousands of EUR	2025	2024	2025	2024	2024
Net Sales	433	554	1,178	1,150	1,936
Cost of sales					
Amortization of capitalized development costs	(307)	(307)	(614)	(614)	(1,227)
Other cost of sales	(44)	(50)	(67)	(99)	(156)
Total cost of sales	(351)	(357)	(681)	(713)	(1,383)
Gross profit	82	197	497	437	553
Impairment of development costs	-	-	-	-	(1,669)
Research and development costs (Note 4)	(1,385)	(3,012)	(2,961)	(7,339)	(12,188)
General and administrative costs	(3,222)	(3,054)	(6,234)	(6,054)	(12,162)
Operating loss	(4,525)	(5,869)	(8,698)	(12,956)	(25,466)
Financial income	744	301	610	3,938	1,927
Financial expenses	(1,664)	(863)	(117)	(883)	(98)
Loss before income taxes	(5,445)	(6,431)	(8,205)	(9,901)	(23,637)
Income taxes	(3)	-	(7)	(2)	(49)
Loss for the period	(5,448)	(6,431)	(8,212)	(9,903)	(23,686)
Attributable to					
Owners of Implantica AG	(5,427)	(6,375)	(8,136)	(9,739)	(23,333)
Non-controlling interests	(21)	(56)	(76)	(164)	(353)
Loss for the period	(5,448)	(6,431)	(8,212)	(9,903)	(23,686)
Earnings per share (Note 5)					
Basic and diluted loss per share Class A (in EUR)	(0.08)	(0.09)	(0.12)	(0.14)	(0.34)
Basic and diluted loss per share Class B (in EUR)	(0.00)	(0.00)	(0.00)	(0.00)	(0.00)

Condensed consolidated statement of profit or loss and other comprehensive income

	Apr to Jun		Jan to Jun		Jan to Dec
in thousands of EUR	2025	2024	2025	2024	2024
Loss for the period	(5,448)	(6,431)	(8,212)	(9,903)	(23,686)
Other comprehensive income					
Remeasurement of net defined benefit liability	56	7	(9)	(69)	46
Total items that will not be reclassified to profit or loss	*56*	*7*	*(9)*	*(69)*	*46*
Translation differences (Note 6)	1,204	1,084	406	(3,450)	(1,469)
Total items that may be reclassified subsequently to profit or loss	*1,204*	*1,084*	*406*	*(3,450)*	*(1,469)*
Other comprehensive income for the period, net of tax	1,260	1,091	397	(3,519)	(1,423)
Total comprehensive income for the period	(4,188)	(5,340)	(7,815)	(13,422)	(25,109)
Attributable to					
Owners of Implantica AG	(4,248)	(5,284)	(8,072)	(13,258)	**(24,756)**
Non-controlling interests	60	(56)	257	(164)	**(353)**
Total comprehensive income for the period	(4,188)	(5,340)	(7,815)	(13,422)	(25,109)

Condensed consolidated statement of financial position

in thousands of EUR	30 Jun 2025	30 Jun 2024	31 Dec 2024
ASSETS			
Current assets			
Cash and cash equivalents (Note 7)	21,930	74,029	64,552
Accounts receivable	500	551	589
Other current receivables	2,296	1,746	1,649
Inventories	196	181	226
Current financial assets (Note 7)	34,383	-	-
Total current assets	59,305	76,507	67,016
Non-current assets			
Property, plant and equipment	253	229	234
Right-of-use assets (Note 9)	-	697	571
Intangible assets (Note 4)	34,659	37,581	35,292
Deferred tax assets	966	986	966
Total non-current assets	35,878	39,493	37,063
Total assets	95,183	116,000	104,079
LIABILITIES AND EQUITY			
Current liabilities			
Trade payable	11	251	297
Financial liabilities	-	298	305
Financial liabilities due to ultimate main shareholder	1	1	1
Other current liabilities	2,034	2,710	2,694
Total current liabilities	2,046	3,260	3,297
Non-current liabilities			
Financial liabilities	-	423	290
Pension liability	363	612	334
Total non-current liabilities	363	1,035	624
Total liabilities	2,409	4,295	3,921
Equity			
Share capital (Note 6)	129,351	129,137	129,351
Capital reserves	370,548	370,548	370,548
Treasury share reserve (Note 6)	(47)	(2)	(71)
Translation differences (Note 6)	14,251	12,197	14,178
Retained earnings	(419,008)	(397,786)	(411,270)
Total equity attributable to owners of Implantica AG	95,095	114,094	102,736
Non-controlling interests	(2,321)	(2,389)	(2,578)
Total equity	92,774	111,705	100,158
Total liabilities and equity	95,183	116,000	104,079

Condensed consolidated statement of cash flows

in thousands of EUR	Apr to Jun 2025	Apr to Jun 2024	Jan to Jun 2025	Jan to Jun 2024	Jan to Dec 2024
Loss for the period	(5,448)	(6,431)	(8,212)	(9,903)	(23,686)
Adjustments for					
Depreciation, amortization and impairment	408	405	816	815	3,300
Financial income	(744)	(301)	(610)	(3,938)	(1,927)
Financial expenses	1,664	863	117	883	98
Income taxes	3	-	7	2	49
Share-based compensation	398	24	431	81	221
Other financial result	(4)	(5)	(11)	(10)	(19)
Change in pension liabilities	11	(5)	21	(11)	72
Other non-cash items	20	(43)	-	(143)	(26)
Changes in net working capital					
Decrease / (increase) accounts receivable	320	(98)	89	(119)	(157)
Decrease / (increase) other current receivables	(354)	(251)	(184)	(757)	(660)
Decrease / (increase) inventories	10	33	30	130	85
(Decrease) / increase trade payable	(29)	222	(286)	251	297
(Decrease) / increase other current liabilities	(174)	(950)	(652)	(283)	(402)
Net cash outflow from operating activities	(3,919)	(6,537)	(8,444)	(13,002)	(22,755)
Cash flows from investing activities					
Purchase of property, plant and equipment	(34)	-	(59)	-	(36)
Investment in intangible assets (Note 4)	-	(25)	(8)	(496)	(406)
Investment in fixed term deposits (Note 7)	-	-	(34,220)	-	-
Interest received	126	300	136	407	787
Net cash inflow/(outflow) from investing activities	92	275	(34,151)	(89)	345
Cash flows from financing activities					
Payment of lease liabilities	(74)	(72)	(146)	(147)	(257)
Interest paid	(3)	(9)	(7)	(15)	(48)
Net cash outflow from financing activities	(77)	(81)	(153)	(162)	(305)
Net increase/(decrease) in cash and cash equivalents	(3,904)	(6,343)	(42,748)	(13,253)	(22,715)
Effect of exchange rate fluctuations on cash held	81	290	126	(640)	(655)
Cash and cash equivalents at beginning of period	25,753	80,082	64,552	87,922	87,922
Cash and cash equivalents at end of period	21,930	74,029	21,930	74,029	64,552

Condensed consolidated statement of changes in equity

in thousands of EUR	Jan to Jun 2025							
	Share capital	Capital reserves	Treasury share reserve	Translation differences	Retained earnings	Total	Non-controlling interests	Total equity
Balance at 31 December 2024	129,351	370,548	(71)	14,178	(411,270)	102,736	(2,578)	100,158
Loss for the period	-	-	-	-	(8,136)	(8,136)	(76)	(8,212)
Other comprehensive income (net)	-	-	-	73	(9)	64	333	397
Total comprehensive income (net)	-	-	-	73	(8,145)	(8,072)	257	(7,815)
Share-based compensation	-	-	24	-	407	431	-	431
Total transactions with shareholders	-	-	24	-	407	431	-	431
Balance at 30 June 2025	129,351	370,548	(47)	14,251	(419,008)	95,095	(2,321)	92,774

in thousands of EUR	Jan to Jun 2024							
	Share capital	Capital reserves	Treasury share reserve	Translation differences	Retained earnings	Total	Non-controlling interests	Total equity
Balance at 31 December 2023	129,137	370,548	(2)	15,647	(388,059)	127,271	(2,225)	125,046
Loss for the period attributable to owners of the Company	-	-	-	-	(9,739)	(9,739)	(164)	(9,903)
Other comprehensive income (net)	-	-	-	(3,450)	(69)	(3,519)	-	(3,519)
Total comprehensive income (net)	-	-	-	(3,450)	(9,808)	(13,258)	(164)	(13,422)
Share-based compensation	-	-	-	-	81	81	-	81
Total transactions with shareholders	-	-	-	-	81	81	-	81
Balance at 30 June 2024	129,137	370,548	(2)	12,197	(397,786)	114,094	(2,389)	111,705

Notes

NOTE 1 General information

Implantica AG (the 'Company') is domiciled at Aeulestrasse 45, 9490 Vaduz, Liechtenstein. These condensed consolidated interim financial statements ('interim financial statements') as at and for the six month ended 30 June 2025 comprise the Company and its subsidiaries (together referred to as the 'Group'). The Group is primarily involved in the research and distribution of medical implants. Implantica AG was admitted to trading on the Nasdaq First North Premier Growth Market in Stockholm in September 2020. Implantica AG is ultimately controlled by the Implantica Founder, Dr. Peter Forsell.

These interim financial statements were authorized for issue by the Company's Board of Directors on 13 August 2025. As of this date, no material events after the reporting date have occurred.

NOTE 2 Summary of significant accounting policies

Basis of preparation

These interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and should be read in conjunction with the Group's consolidated financial statements as at and for the year ended 31 December 2024 ('last financial statements'). These interim financial statements do not include all of the information required for a complete set of financial statements prepared in accordance with IFRS Accounting Standards. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last financial statements.

For the preparation of these financial statements the historical cost basis except for all those assets and liabilities measured at fair value has been applied. All amounts are presented in EUR, and are rounded to the nearest thousand of EUR with the consequence that the rounded amounts may not add to the rounded total in all cases. All ratios and variances are calculated using the underlying amounts rather than the rounded amounts.

Critical accounting estimates and judgements

In preparing these interim financial statements, management has made judgements and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.

NOTE 3 General accounting policies

The accounting policies applied in these interim financial statements are the same as those applied in the Group's consolidated financial statements as at and for the year ended 31 December 2024.

There were no new standards or amendments to existing standards that have a material effect on the Group's interim financial statements.

Accounting standards issued but not yet effective

A number of new accounting standards and amendments to accounting standards are effective for annual periods beginning after 1 January 2025 and earlier application is permitted. The Group has not early adopted any of the forthcoming new or amended accounting standards in preparing these condensed consolidated interim financial statements.

NOTE 4 Intangible assets

	Jan to Jun	
in thousands of EUR	2025	2024
Net carrying amount at 1 January	35,292	38,163
Additions Jan to Mar	-	54
Additions Apr to Jun	-	4
Amortization Jan to Mar	(316)	(318)
Amortization Apr to Jun	(316)	(318)
Translation differences	(1)	(4)
Net carrying amount at 30 June	34,659	37,581

For the second quarter research and development costs in the amount of EUR 1,385 thousand were recognized in profit or loss since the conditions for capitalization as intangible assets for these costs are not met (YTD: EUR 2,961 thousand).

NOTE 5 Earnings per share

	Apr to Jun		Jan to Jun		Jan to Dec
in thousands of EUR	2025	2024	2025	2024	2024
Loss for the period attributable to owners of Implantica AG	(5,427)	(6,375)	(8,136)	(9,739)	(23,333)
Weighted average % of Class A share capital in total share capital	83.8%	83.8%	83.8%	83.8%	83.8%
Weighted average % of Class B share capital in total share capital	16.2%	16.2%	16.2%	16.2%	16.2%
Class A shares					
Loss for the period attributable to Class A shareholders	(4,548)	(5,341)	(6,818)	(8,159)	(19,549)
Weighted average number of outstanding Class A shares	58,188,585	58,110,245	58,183,946	58,110,245	58,111,738
Basic and diluted (loss) per share Class A (in EUR)	(0.08)	(0.09)	(0.12)	(0.14)	(0.34)
Class B shares					
Loss for the period attributable to Class B shareholders	(879)	(1,034)	(1,318)	(1,580)	(3,784)
Weighted average number of Class B shares	1,125,000,000	1,125,000,000	1,125,000,000	1,125,000,000	1,125,000,000
Basic and diluted (loss) per share Class B (in EUR)	(0.00)	(0.00)	(0.00)	(0.00)	(0.00)

Earnings per category of shares

Earnings per class of shares (Note 6) are calculated on the basis of the net loss attributable to the shareholders of Implantica AG based on their portion of the share capital and the average number of outstanding shares (i.e. excluding treasury shares)

Anti-dilutive effect of potential outstanding shares

The impact of share-based compensation arrangements was not considered in the diluted earnings per share calculation for Class A shares for the periods presented because due to the net loss for these periods their effect would have been anti-dilutive.

NOTE 6 Equity

Share capital

The fully paid in share capital of the Group amounts to CHF 138,923 thousand (EUR 129,351 thousand) and is divided into 58,211,537 registered shares with a nominal value of CHF 2.00 each (Class A) and 1,125,000,000 with a nominal value of CHF 0.02 each (Class B). As of 30 June 2025 a total number of 21,980 Class A shares are held by the Group (31 December 2024: 33,159).

During the second quarter 2025 the Group delivered 8,842 Class A shares to employees as part of existing share-based payment commitments (YTD: 11,179).

Translation differences

During the second quarter the EUR/CHF exchange rate increased from 1.049 to 1.070. As a result, the group recognized a total gain of EUR 1,204 thousand in other comprehensive income related to the translation of financial statements of foreign operations and net investments in foreign operations (YTD: EUR 406 thousand).

NOTE 7 Cash and cash equivalents and financial assets

On 9 January 2025 the Group entered into a EUR 29,000 thousand and a SEK 60,000 thousand (EUR 5,220 thousand) six months term deposit agreements with an A+ rated Swiss bank. The interest rate is 2.65% for the EUR denominated and 2.13% for the SEK denominated fixed term deposit. As the duration is more than three months these instruments are classified as current financial assets.

NOTE 8 Equity-based compensation

During the period the Group granted a total number of 752,980 stock options to executive management and one employee, with vesting periods from 8 months to 5 years and a total fair value of EUR 2,131 thousand. The options are settled by delivering fully paid Class A Implantica AG shares at no cost (i.e. exercise price CHF 0).

In addition, the Group granted restricted stock units to an employee with a total value of EUR 50 thousand of which EUR 40 thousand immediately vested and EUR 10 thousand vest in one year.

NOTE 9 Leases

During the period, the Group terminated a lease originally set to end on 31 December 2026, incurring no penalties. Consequently, right-of-use assets of EUR 403 thousand and lease liabilities of EUR 423 thousand were derecognised through profit or loss. After the quarter end, the Group entered a new two-year lease commencing at the beginning of August 2025.

Other

Telephone conference

Implantica will hold a teleconference on 14 August 2025 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference:

Webcast

If you wish to participate via webcast, please use the following link:

https://implantica.events.inderes.com/q2-report-2025

Dial-in

If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.

https://conference.inderes.com/teleconference/?id=5009464

Financial calendar

31 October 2025	Interim Report Q3 2025

Listing

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company is traded under the ticker symbol IMP A SDB and ISIN code SE0014855029.

Disclaimer statement

Some statements herein are forward-looking, and the actual outcome could be materially different. In addition to the factors explicitly commented upon, the actual outcome could be materially affected by other factors, for example: the impact of undesired side effects related to existing or future products, failures in handling of the quality system, obstacles in obtaining CE and FDA approvals and re-certifications, products may fail to become subject to insurance and reimbursement policies and risk not gaining widespread acceptance, clinical trials may prove to be unsuccessful and the impact of competing products.

Contacts

Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone: +41 (0)79 335 09 49
E-mail: nicole.pehrsson@implantica.com

Peter Forsell, CEO
E-mail: peter.forsell@implantica.com

Andreas Öhrnberg, CFO
E-mail: andreas.oehrnberg@implantica.com

Implantica AG
Aeulestrasse 45
9490 Vaduz
Liechtenstein

www.implantica.com